



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

Habener and Mojsov

U.S. Patent No.: 6,849,708

Date Issued: February 1, 2005

Based on Appl. No.: 09/635,679

Filed: August 10, 2000

For: **Insulinotropic Hormone and Uses
Thereof**

Confirmation No.: 6862

Art Unit: 1645

Examiner: Minnifield, Nita M.

Atty. Docket: 0609.1090009/MAC/ALS

**Petition Under 37 C.F.R. §1.324 to Correct
Inventorship in a Patent**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees petition to correct inventorship in the captioned patent. Specifically,
Patentees petition to change the inventorship in this patent from **Joel F. Habener** to **Joel
F. Habener and Svetlana Mosjov**.

This petition is accompanied by:


- (1) A statement from each person to be added as an inventor, stating that the error in inventorship was made without deceptive intent on his or her part;
- (2) A statement from the current named inventor agreeing to the change in inventorship;
- (3) The written consent of the assignee of both inventors;
- (4) A Statement under 37 C.F.R. § 3.73(b) executed by the assignee named in part (3); and

- (5) The petition fee of **\$130.00** as set forth under 37 C.F.R. §1.20(b), in our attached PTO-2038 Credit Card Payment Form.

Patentees hereby authorize the U.S. Patent and Trademark Office to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Aaron L. Schwartz
Attorney for Patentees
Registration No. 48,181

Date: August 18, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

423493_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Habener and Mojsov

U.S. Patent No.: 6,849,708

Date Issued: February 1, 2005

Based on Appl. No.: 09/635,679

Filed: August 10, 2000

For: **Insulinotropic Hormone and Uses
Thereof**

Confirmation No.: 6862

Art Unit: 1645

Examiner: Minnifield, Nita M.

Atty. Docket: 0609.1090009/MAC/ALS


**Statement Under 37 C.F.R. § 1.324(b)(2) from the
Currently Named Inventor**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

I am the currently named inventor in the above-captioned patent. I agree to the change of inventorship to add Svetlana Mojsov as a coinventor of this patent.

Signed Joel F. Habener Date: 5/26/05
Joel F. Habener



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Habener and Mojsov

U.S. Patent No.: 6,849,708

Date Issued: February 1, 2005

Based on Appl. No.: 09/635,679

Filed: August 10, 2000

For: **Insulinotropic Hormone and Uses
Thereof**

Confirmation No.: 6862

Art Unit: 1645

Examiner: Minnifield, Nita M.

Atty. Docket: 0609.1090009/MAC/ALS


**Statement Under 37 C.F.R. § 1.324(b)(1) of a Person
To Be Added as an Inventor**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

I am a coinventor of the invention of one or more claims in the above-captioned patent. The inventorship error of failing to include me as an inventor of this patent occurred without any deceptive intention on my part. I have read and understand 37 C.F.R. § 10.18(b).

Signed: Svetlana Mojsov Date: 6/10/05
Svetlana Mojsov



PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

0609.1090009/MAC/ALS

Applicant/Patent Owner: The General Hospital CorporationApplication No./Patent No.: 6,849,708 Filed/Issue Date: February 1, 2005Entitled: Insulintropic Hormone and Uses ThereofThe General Hospital Corporation, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Joel F. Habener To: The General Hospital Corporation
The document was recorded in the United States Patent and Trademark Office at
Reel 5885, Frame 712, or for which a copy thereof is attached.
2. From: Joel F. Habener To: The General Hospital Corporation
The document was recorded in the United States Patent and Trademark Office at
Reel 13774, Frame 234, or for which a copy thereof is attached.
3. From: Svetlana Mojssov To: The General Hospital Corporation
The document was recorded in the United States Patent and Trademark Office at
Reel 13372, Frame 792, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

FRANCES TONEGLIZZO, Ph.D.
Signature

DIRECTOR

CORPORATE SPONSORED RESEARCH AND LICENSING


4/28/05
Date

Telephone Number

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

Habener and Mojsov

U.S. Patent No.: 6,849,708

Date Issued: February 1, 2005

Based on Appl. No.: 09/635,679

Filed: August 10, 2000

For: **Insulinotrophic Hormone and Uses
Thereof**

Confirmation No.: 6862

Art Unit: 1645

Examiner: Minnifield, Nita M.

Atty. Docket: 0609.1090009/MAC/ALS

Consent of the Assignee Under 37 C.F.R. § 1.324(b)(3)Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The General Hospital Corporation, assignee of the entire right, title and interest of both the originally named inventor of the captioned patent and Svetlana Mojsov, consents to the change in inventorship from Joel F. Habener to Joel F. Habener and Svetlana Mojsov.

For: The General Hospital CorporationSignature: Type or Print Name: FRANCES TONESUZZO, Ph.D.Title: MANAGERDate: 8/21/05

CORPORATE SPONSORED RESEARCH AND LICENSING

381153v1